PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8680521

Primary bone malignancies in children.

M Hahn·J P Dormans
View original source ↗Export metadata ↓

Abstract

The evaluation and treatment of primary bone malignancies in children have evolved considerably over the past decade, with a measurable improvement in prognosis. Disease-free survival has improved mainly due to intensive multiple-agent chemotherapy, refinement in radiotherapeutic techniques, better imaging, and wide surgical resection. Reconstruction techniques after "limb-sparing" surgery have used allograft, composite allograft-prosthesis, or "expandable" prostheses reconstruction after adequate removal of the tumor with wide margins. The diagnosis and understanding of these tumor has also improved with advances in molecular genetics. Both osteosarcoma and Ewing's sarcoma treatment have undergone this dramatic change; recent advances in molecular genetics, treatment, magnetic resonance imaging, and "limb-sparing" surgery are highlighted.

Explore related subjects

Antineoplastic AgentsBone NeoplasmsBone TransplantationChildHumansMagnetic Resonance ImagingOsteosarcomaPrognosisSarcoma, EwingTreatment OutcomeJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Hahn, J P Dormans. 1996. Primary bone malignancies in children.. https://doi.org/10.1097/00008480-199602000-00016

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2021

Deep generative neural network for accurate drug response imputation.

Drug response differs substantially in cancer patients due to inter- and intra-tumor heterogeneity. Particularly, transcriptome context, especially tumor microenvironment, has been shown playing a significant role in shaping the actual treatment outcome. In this study, we develop a deep variational autoencoder (VAE) model to compress thousands of genes into latent vectors in a low-dimensional space. We then demonstrate that these encoded vectors could accurately impute drug response, outperform standard signature-gene based approaches, and appropriately control the overfitting problem. We apply rigorous quality assessment and validation, including assessing the impact of cell line lineage, cross-validation, cross-panel evaluation, and application in independent clinical data sets, to warrant the accuracy of the imputed drug response in both cell lines and cancer samples. Specifically, the expression-regulated component (EReX) of the observed drug response achieves high correlation across panels. Using the well-trained models, we impute drug response of The Cancer Genome Atlas data and investigate the features and signatures associated with the imputed drug response, including cell line origins, somatic mutations and tumor mutation burdens, tumor microenvironment, and confounding factors. In summary, our deep learning method and the results are useful for the study of signatures and markers of drug response.

Antineoplastic Agents↗
PubMed2001

Synthesis of polyhydroxysterols (I): synthesis of 24-methylenecholest-4-en-3beta,6beta-diol, a cytotoxic natural hydroxylated sterol.

Starting from stigmasterol (2), 24-methylenecholest-4-en-3beta, 6beta-diol (1), a cytotoxic natural dihydroxylated sterol, was synthesized via 10 steps in 20% overall yield. The introduction of a side-chain of sterol was achieved by solid-liquid phase-transfer Wittig reaction using (3-methyl-2-oxo)butyltriphenylarsonium bromide (12) and K(2)CO(3). Construction of the steroidal nucleus was finished by the addition of 3beta-acetoxycholest-5,6-en-24-one (7) with NBA in dioxane under ambient temperature and by the elimination of 3beta, 6beta-diacetoxy-5a-bromocholestane-24-one (9). The spectral data of the synthetic product (1) are completely consistent with those of the natural compound (1).

Antineoplastic Agents↗